University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Marko Stojanovic in
Google Scholar
PubMed
Search for other papers by Zida Wu in
Google Scholar
PubMed
Search for other papers by Craig E Stiles in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Dragana Miljic in
Google Scholar
PubMed
Insitute of Medical Statistics and Informatics, Belgrade, Serbia
Search for other papers by Ivan Soldatovic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Sandra Pekic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Mirjana Doknic in
Google Scholar
PubMed
University of Belgrade, Medical Faculty, Belgrade, Serbia
Search for other papers by Milan Petakov in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
-secreting macroadenomas, resistant to somatostatin analogue (SA) treatment ( 17 , 18 ). AIP is thought to play an important role in the response to SA in acromegaly ( 19 ). Neither the exact mechanism of AIP influence on proliferation inhibition, nor its possible role in
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by David A Cano in
Google Scholar
PubMed
Search for other papers by Eva Venegas-Moreno in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Elena Dios in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Alvaro Flores-Martínez in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Alfonso Soto-Moreno in
Google Scholar
PubMed
thyrotropinomas are rarer ( 1 , 2 , 3 ). Treatment of pituitary adenomas varies according to the pituitary adenoma sub-type. Responses to therapy are variable due to heterogeneity among patient profiles and tumor characteristics. For instance, acromegaly
Search for other papers by Julie M Silverstein in
Google Scholar
PubMed
Introduction Acromegaly is a rare hormonal condition that develops most commonly from benign somatotroph pituitary adenomas and has a prevalence of 36–69 cases per million and an incidence of 3–4 cases per million per year (1, 2, 3, 4) . However
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Héctor Pian in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Alberto Acitores Cancela in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Endoscopic Skull Base Unit, Department of Neurosurgery, Hospital Universitario HM Puerta del Sur, Madrid, Spain
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
Introduction Acromegaly is a rare disease characterized by the overproduction of growth hormone (GH), which is commonly secreted by a pituitary adenoma (PA). Because of cardiovascular, respiratory, and metabolic comorbidities, patients with
Hôpital de Cayenne, Service d’Endocrinologie et des Maladies Métaboliques, Cayenne, Guyane Française
Search for other papers by Nadia Sabbah in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Céline Piedvache in
Google Scholar
PubMed
Search for other papers by Séverine Trabado in
Google Scholar
PubMed
Search for other papers by Tristan Verdelet in
Google Scholar
PubMed
Search for other papers by Catherine Cornu in
Google Scholar
PubMed
Search for other papers by Jean-Claude Souberbielle in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Introduction IGF-1 measurement is important for the diagnosis and management of patients with growth hormone (GH) deficiency or acromegaly as well as in their follow-up ( 1 , 2 ). We previously established normative data for six IGF-I assays
Diagnósticos da América SA, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Paula Bruna Araujo in
Google Scholar
PubMed
Neuroendocrinology Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Endocrinology Unit, Hospital Federal de Bonsucesso, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Search for other papers by Carlos Henrique de Azeredo Lima in
Google Scholar
PubMed
Search for other papers by Liana Ogino in
Google Scholar
PubMed
National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Aline H S Camacho in
Google Scholar
PubMed
Search for other papers by Leila Chimelli in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
hydrocarbon receptor-interacting protein ( AIP ) gene mutations ( AIPmut ) were first described by Vierimaa and coworkers in 2006 ( 3 ). This study has found AIPmut in seemingly sporadic acromegaly patients and in familial isolated pituitary adenomas (FIPA
Neuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Search for other papers by Nidan Qiao in
Google Scholar
PubMed
pituitary neoplasms, acromegaly, Cushing’s disease, craniopharyngioma and growth hormone deficiency. More than half of the studies were published in the recent 2 years. Table 2 Summary of studies on sellar region disease using machine learning methods
Department of Medicine, Division of Endocrinology and Centre for Endocrine Tumors, Leiden University Medical Centre, Leiden, The Netherlands
Department of Neurosurgery, University Neurosurgical Centre Holland (UNCH), Leiden University Medical Centre, Haaglanden Medical Centre and Haga Teaching Hospitals, Leiden and The Hague, The Netherlands
Search for other papers by Amir H Zamanipoor Najafabadi in
Google Scholar
PubMed
Search for other papers by Merel van der Meulen in
Google Scholar
PubMed
Search for other papers by Ana Luisa Priego Zurita in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Wouter R van Furth in
Google Scholar
PubMed
Search for other papers by Evangelia Charmandari in
Google Scholar
PubMed
Search for other papers by Olaf Hiort in
Google Scholar
PubMed
Search for other papers by Alberto M Pereira in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Diana Vitali in
Google Scholar
PubMed
Search for other papers by Johan P de Graaf in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
. Pituitary adenomas comprise non-hormone-producing adenomas and adenomas producing an excess of growth hormone (acromegaly), adrenocorticotropic hormone (Cushing’s disease), prolactin (prolactinoma), thyrotropin hormone (TSH-producing adenoma), and
Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Search for other papers by Swati Ramteke-Jadhav in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Virendra Patil in
Google Scholar
PubMed
Search for other papers by Puja Thadani in
Google Scholar
PubMed
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Search for other papers by Atul Goel in
Google Scholar
PubMed
Search for other papers by Sridhar Epari in
Google Scholar
PubMed
Search for other papers by Naina Goel in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
hyperprolactinemia. Another patient (case 7) had headache, amenorrhoea, and clinical features of acromegaly. On hormonal evaluation, she had high IGF1 levels and mild hyperprolactinemia ( Table 1 ). In a recent extensive review including 69 patients with GCTs
Search for other papers by Caiyan Mo in
Google Scholar
PubMed
Search for other papers by Tao Tong in
Google Scholar
PubMed
Search for other papers by Ying Guo in
Google Scholar
PubMed
Search for other papers by Zheng Li in
Google Scholar
PubMed
Search for other papers by Liyong Zhong in
Google Scholar
PubMed
-term overproduction of GH and IGF-1 promotes the overgrowth of soft tissues, bones, and cartilages throughout the body, leading to a series of typical signs and symptoms of acromegaly or gigantism, and can cause multi-organ/system complications such as respiratory